Kyle J Burghardt1, Berhane Seyoum2, Sabrina E Dass1, Elani Sanders1, Abdullah Mallisho2, Zhengping Yi3. 1. Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan. 2. Division of Endocrinology, Wayne State University School of Medicine, Detroit, Michigan. 3. Department of Pharmaceutical Science, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan.
Abstract
STUDY OBJECTIVE: Atypical antipsychotics cause insulin resistance that leads to an increased risk of diabetes mellitus and cardiovascular disease. Skeletal muscle is the primary tissue for uptake of glucose, and its dysfunction is considered one of the primary defects in the development of insulin resistance. Protein kinase B (AKT) plays an important role in overall skeletal muscle health and glucose uptake into the muscle. The objective of this study was to measure AKT isoform-specific gene methylation differences in the skeletal muscle of patients with bipolar disorder treated with atypical antipsychotic or mood stabilizer maintenance therapy. DESIGN: Cross-sectional observational study. SETTING: Clinical research services center at an academic center. PATIENTS: Thirty patients with a confirmed diagnosis of bipolar disorder who were treated with either an atypical antipsychotic (16 patients) or mood stabilizer (14 patients) at a consistent dose for at least 3 months. INTERVENTIONS: A fasting skeletal muscle biopsy was performed in the vastus lateralis in each patient. Patients also underwent fasting blood sample collection and a standard 75-g oral glucose tolerance test. MEASUREMENTS AND MAIN RESULTS: Skeletal muscle DNA methylation near the promoter region for three genes, AKT1, AKT2, and AKT3, was measured by methylation-sensitive high-resolution melting. Gene methylation was analyzed based on atypical antipsychotic versus mood stabilizer maintenance therapy. Associations between gene methylation, insulin resistance, and glucose tolerance were also analyzed. In patients treated with atypical antipsychotics, AKT1 and AKT2 methylation was increased compared with patients treated with mood stabilizers (p=0.03 and p=0.02, respectively). In addition, for patients receiving atypical antipsychotics, a positive trend for AKT2 hypermethylation with increasing insulin resistance was observed, whereas for patients receiving mood stabilizers, a trend for decreased AKT2 methylation with increasing insulin resistance was observed. CONCLUSION: Overall, our findings suggest that the AKT gene is differentially methylated in the skeletal muscle of patients taking atypical antipsychotics or mood stabilizer maintenance therapy. These results may direct future approaches to reduce the harmful adverse effects of atypical antipsychotic treatment.
STUDY OBJECTIVE: Atypical antipsychotics cause insulin resistance that leads to an increased risk of diabetes mellitus and cardiovascular disease. Skeletal muscle is the primary tissue for uptake of glucose, and its dysfunction is considered one of the primary defects in the development of insulin resistance. Protein kinase B (AKT) plays an important role in overall skeletal muscle health and glucose uptake into the muscle. The objective of this study was to measure AKT isoform-specific gene methylation differences in the skeletal muscle of patients with bipolar disorder treated with atypical antipsychotic or mood stabilizer maintenance therapy. DESIGN: Cross-sectional observational study. SETTING: Clinical research services center at an academic center. PATIENTS: Thirty patients with a confirmed diagnosis of bipolar disorder who were treated with either an atypical antipsychotic (16 patients) or mood stabilizer (14 patients) at a consistent dose for at least 3 months. INTERVENTIONS: A fasting skeletal muscle biopsy was performed in the vastus lateralis in each patient. Patients also underwent fasting blood sample collection and a standard 75-g oral glucose tolerance test. MEASUREMENTS AND MAIN RESULTS: Skeletal muscle DNA methylation near the promoter region for three genes, AKT1, AKT2, and AKT3, was measured by methylation-sensitive high-resolution melting. Gene methylation was analyzed based on atypical antipsychotic versus mood stabilizer maintenance therapy. Associations between gene methylation, insulin resistance, and glucose tolerance were also analyzed. In patients treated with atypical antipsychotics, AKT1 and AKT2 methylation was increased compared with patients treated with mood stabilizers (p=0.03 and p=0.02, respectively). In addition, for patients receiving atypical antipsychotics, a positive trend for AKT2 hypermethylation with increasing insulin resistance was observed, whereas for patients receiving mood stabilizers, a trend for decreased AKT2 methylation with increasing insulin resistance was observed. CONCLUSION: Overall, our findings suggest that the AKT gene is differentially methylated in the skeletal muscle of patients taking atypical antipsychotics or mood stabilizer maintenance therapy. These results may direct future approaches to reduce the harmful adverse effects of atypical antipsychotic treatment.
Authors: J Engl; M Laimer; A Niederwanger; M Kranebitter; M Starzinger; M T Pedrini; W W Fleischhacker; J R Patsch; C F Ebenbichler Journal: Mol Psychiatry Date: 2005-12 Impact factor: 15.992
Authors: Oliver Tschopp; Zhong-Zhou Yang; Daniela Brodbeck; Bettina A Dummler; Maja Hemmings-Mieszczak; Takashi Watanabe; Thomas Michaelis; Jens Frahm; Brian A Hemmings Journal: Development Date: 2005-06-01 Impact factor: 6.868
Authors: E Ferrannini; D C Simonson; L D Katz; G Reichard; S Bevilacqua; E J Barrett; M Olsson; R A DeFronzo Journal: Metabolism Date: 1988-01 Impact factor: 8.694
Authors: Davy Vancampfort; Christoph U Correll; Britta Galling; Michel Probst; Marc De Hert; Philip B Ward; Simon Rosenbaum; Fiona Gaughran; John Lally; Brendon Stubbs Journal: World Psychiatry Date: 2016-06 Impact factor: 49.548
Authors: Myoung-Sun Roh; Myoung Suk Seo; Yeni Kim; Se Hyun Kim; Won Je Jeon; Yong Min Ahn; Ung Gu Kang; Yong Sung Juhnn; Yong Sik Kim Journal: Exp Mol Med Date: 2007-06-30 Impact factor: 8.718
Authors: Jiaqi Zhou; Miao Li; Xueying Wang; Yuwen He; Yan Xia; John A Sweeney; Richard F Kopp; Chunyu Liu; Chao Chen Journal: Front Neurosci Date: 2021-05-13 Impact factor: 4.677
Authors: Kristen M Ward; Kyle Burghardt; A Zarina Kraal; Andrew Jaeger; Larisa Yeomans; Cora McHugh; Alla Karnovsky; Kathleen A Stringer; Vicki L Ellingrod Journal: Front Psychiatry Date: 2021-05-25 Impact factor: 4.157